An interventional study of Heparin Anticoagulation and Regional Anticoagulation Procedure (RAP) in End-Stage Renal Disease, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.
Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 47th largest by planned enrollment of the 105 interventional ones that give a count, is one of 10 that started in 2024, is one of 55 with no phase, reaches primary completion later than 9 of the 32 other live ones, and was the 134th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+ · Healthy volunteers
University of Avignon · Sites in France
Ages 20–79
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+ · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 6–17 · Men only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 16 · Phase 3 26 · Phase 4 9
First in 1994; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 70 across the 105 interventional studies, 177 across the 40 observational. Of the 90 that completed or were terminated, 15 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 145 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 4 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Failure, Chronic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06692231Centre Hospitalier de VichyImpact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients | 2026-11-30 |
| NCT06474169Centre Hospitalier Régional d'OrléansAssessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients. | 2026-12 |
| NCT06595680Hospices Civils de LyonDevelopment of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins | 2027-01-22 |
| NCT06887075University Hospital, BordeauxSystemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation | 2027-02-15 |
| NCT05753930Hansa Biopharma ABImlifidase Prior to Kidney Transplant in Highly Sensitised Children | 2027-02-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 145 studies in Kidney Failure, Chronic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intermittent hemodialysis is a complex technique which requires careful monitoring of anticoagulation levels to prevent clotting and reduce the risk of bleeding complications. Dialysis patients often exhibit hypercoagulable tendencies due to uremic state, turbulent blood flows in dialysis procedures, and thrombogenic exposure to artificial surfaces of dialysis tubing. Patients with ESRD may experience both dialyzer clotting and excessive bleeding, so individualized heparin dosing and periodic adjustments are necessary to ensure adequate anticoagulation during hemodialysis. The ideal anticoagulant should prevent thrombosis while minimizing the risk of intra- and interdialytic bleeding. The use of heparin carries risks such as worsening of osteoporosis and dyslipidemia, allergic reactions like pruritus, and the potential for life-threatening heparin-induced thrombocytopenia (HIT) for which avoidance of heparin is necessary during dialysis.Heparin, in both its unfractionated heparin (UFH) and low molecular weight heparin (LMWH) forms, is the most commonly used anticoagulant, though evidence comparing their efficacy and risk of bleeding remains inconclusive. End-stage renal disease (ESRD) patients, who are already at higher risk of serious bleeding, may benefit from regional anticoagulation (RA) techniques, as they typically receive around 600,000 IU of heparin per year. The investigators performed routinely a simplified regional anticoagulation procedure (RAP) using a constant calcium re-injection rate over the time to avoid hypocalcemia. This procedure eliminates the need for citrate infusion and calcium monitoring, and reduces nurse workload in a chronic dialysis unit. The investigators compared 21 chronic dialysis patients with 198 RA and 195 heparin sessions, where each patient acted as their own control. None of them were on VKA during the RA sessions, 62% were on single anti-platelet therapy and 14% were on dual anti-platelet therapy. The dialysis session success rate was 94% in the RA group and 97% in the heparin group, with no significant differences (p=0.22). The circuit loss rate was 1.5% per RA session and 0.5% per heparin session (p=0.23), and the early blood restitution rate was 3% and 1.5% (p=0.50) in the RA and heparin groups, respectively
Hypothesis: RAP can be as effective as systemic anticoagulation with heparin for intermittent dialysis in chronic hemodialysis patients, with the potential to reduce the rate of hemorrhagic events
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Heparin Anticoagulation
Procedure: Regional Anticoagulation Procedure (RAP)
Conventional dialysis with heparin as anticoagulant treatment
Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
Demonstrate the non-inferiority of the regional anticoagulation procedure compared to heparin anticoagulation on the dialysis sessions success three times per week
The primary endpoint will be the rate of dialysis sessions success over 6 months between two therapeutic strategies: * Regional anticoagulation procedure (RAP) * Heparin anticoagulation
Time frame: 6 months
Compare between the groups clinical Impact at each dialyses session on bypass loss
Rate of bypass loss
Time frame: 6 months
Compare between the groups clinical Impact at each dialyses session on early bypass restitution
Rate of early bypass restitution (defined as a restitution 30 minutes or more before the end of the prescribed time)
Time frame: 6 months
Compare between the groups clinical Impact at each dialyses session on dialysis duration
Mean difference of dialysis duration over 6 month between the groups
Time frame: 6 months
Compare between the groups clinical Impact at each dialyses session on fistula compression time extended more than 10 minutes
Rate of fistula compression time extended more than 10 minutes after a dialysis session
Time frame: 6 months
Compare between the groups clinical Impact during the total duration of the study on incidence of hemorrhagic events
Incidence rate of hemorrhagic events
Time frame: 6 months
Compare between the groups clinical Impact during the total duration of the study on dialysis adequacy
Time average-dialysis adequacy difference defined by the average kt/v over 6 months
Time frame: 6 months
Compare between the groups clinical Impact during the total duration of the study on relative effects on phosphocalcic balance
Mean difference at months +6 and time-average evolution over 6 month for calcium, phosphor, bone-specific alkaline phosphatase and parathyroid hormone concentration between the groups
Time frame: 6 months
Compare between the groups clinical Impact during the total duration of the study on incidence of Hyperparthyroidism
Rate of hyperparathyroidism defined par PTH \> 9N at month +6
Time frame: 6 months
Compare between the groups clinical Impact during the total duration of the study on incidence of non-hemorrhagic heparin-related complications
Rate of non-hemorrhagic heparin-related complications: 1. In the heparin group: heparin-induced thrombocytopenia, 2. Between the groups: hyperkalemia, hypertriglyceridemia, hypersensitivity reactions, pruritus at months +6
Time frame: 6 months
Compare between the groups clinical Impact during the total duration of the study on incidence of cardiovascular-related mortality and major cardiovascular events (MACE)
Incidence rate of MACE at months +6
Time frame: 6 months
Compare between the groups clinical Impact during the total duration of the study on global mortality
All-cause mortality rate at month +6
Time frame: 6 months
Compare between the groups the tolerance of per-dialytic hypotension
Rate of per-dialytic hypotension over 6 months
Time frame: 6 months
Compare between the groups the tolerance of adverse events
Rate of adverse events over 6 months
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Sep 2026, 26 months after the start.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 26 months is above that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →